MADRIGAL PHARMACEUTICALS, INC.MDGLEarnings & Financial Report
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.
Revenue
$137.3M
Gross Profit
$132.7M
Operating Profit
$-79.3M
Net Profit
$-73.2M
Gross Margin
96.7%
Operating Margin
-57.8%
Net Margin
-53.4%
YoY Growth
N/A
EPS
$-3.32
MADRIGAL PHARMACEUTICALS, INC. Q1 FY2025 Financial Summary
MADRIGAL PHARMACEUTICALS, INC. reported revenue of $137.3M for Q1 FY2025, with a net profit of $-73.2M (up 50.4% YoY) (-53.4% margin). Cost of goods sold was $4.5M, operating expenses totaled $212.0M.
Key Financial Metrics
| Total Revenue | $137.3M |
|---|---|
| Net Profit | $-73.2M |
| Gross Margin | 96.7% |
| Operating Margin | -57.8% |
| Report Period | Q1 FY2025 |
MADRIGAL PHARMACEUTICALS, INC. Annual Revenue by Year
MADRIGAL PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $958.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $958.4M |
| 2023 | $0 |
| 2022 | $0 |
MADRIGAL PHARMACEUTICALS, INC. Quarterly Revenue & Net Profit History
MADRIGAL PHARMACEUTICALS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $321.1M | +210.8% | $-58.6M | -18.2% |
| Q3 FY2025 | $287.3M | +362.0% | $-114.2M | -39.8% |
| Q2 FY2025 | $212.8M | +1353.8% | $-42.3M | -19.9% |
| Q1 FY2025 | $137.3M | — | $-73.2M | -53.4% |
| Q4 FY2024 | $103.3M | — | $-59.4M | -57.5% |
| Q3 FY2024 | $62.2M | — | $-107.0M | -172.0% |
| Q1 FY2024 | $0 | — | $-147.5M | N/A |
| Q4 FY2023 | $0 | — | $-112.2M | N/A |
Income Statement
| Q4 2023 | Q1 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $62.2M | $103.3M | $137.3M | $212.8M | $287.3M | $321.1M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | 1353.8% | 362.0% | 210.8% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $640.5M | $1.08B | $1.07B | $1.04B | $996.6M | $1.02B | $1.36B | $1.26B |
| Liabilities | $235.2M | $231.5M | $296.1M | $287.9M | $286.0M | $319.4M | $736.7M | $656.9M |
| Equity | $405.3M | $850.8M | $777.2M | $754.4M | $710.6M | $696.0M | $625.7M | $602.7M |
Cash Flow
| Q4 2023 | Q1 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-79.9M | $-149.2M | $-67.0M | $-104.5M | $-88.9M | $-47.1M | $79.8M | $-133.5M |